{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T20:13:36Z","timestamp":1780604016346,"version":"3.54.1"},"reference-count":135,"publisher":"Informa UK Limited","issue":"3","funder":[{"name":"the National Institute of Allergy and Infectious Diseases (NIAID), U.S. National Institutes of Health (NIH) under project number","award":["ZIA AI000904"],"award-info":[{"award-number":["ZIA AI000904"]}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Investigational Drugs"],"published-print":{"date-parts":[[2022,3,4]]},"DOI":"10.1080\/13543784.2022.2040015","type":"journal-article","created":{"date-parts":[[2022,2,7]],"date-time":"2022-02-07T10:41:27Z","timestamp":1644230487000},"page":"263-279","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":13,"title":["Investigational agents for the treatment of methicillin-resistant\n                    <i>Staphylococcus aureus<\/i>\n                    (MRSA) bacteremia: progress in clinical trials"],"prefix":"10.1080","volume":"31","author":[{"given":"Dylan J.","family":"Burgin","sequence":"first","affiliation":[{"name":"Laboratory of Bacteriology, National Institute of Allergy and Infectious Diseases, National Institutes of Health","place":["Bethesda, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Liu","sequence":"additional","affiliation":[{"name":"Laboratory of Bacteriology, National Institute of Allergy and Infectious Diseases, National Institutes of Health","place":["Bethesda, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger C.","family":"Hsieh","sequence":"additional","affiliation":[{"name":"Laboratory of Bacteriology, National Institute of Allergy and Infectious Diseases, National Institutes of Health","place":["Bethesda, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren R.","family":"Heinzinger","sequence":"additional","affiliation":[{"name":"Laboratory of Bacteriology, National Institute of Allergy and Infectious Diseases, National Institutes of Health","place":["Bethesda, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Otto","sequence":"additional","affiliation":[{"name":"Laboratory of Bacteriology, National Institute of Allergy and Infectious Diseases, National Institutes of Health","place":["Bethesda, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,2,14]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12144"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.arcmed.2005.02.005"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu410"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2013.10.015"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.05022-11"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1086\/345476"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6809e1"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2011.03679.x"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.9778\/cmajo.20140018"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz498"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2019.10.003"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq146"},{"key":"e_1_3_5_15_1","article-title":"Vancomycin","author":"Patel S","year":"2021","unstructured":"Patel S, Preuss CV, Bernice F, Vancomycin, StatPearls, 2021;Treasure Island (FL)","journal-title":"StatPearls"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01568-12"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00700-07"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1086\/491712"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiph.2020.07.008"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-010-1140-7"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2017.06.017"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00904-08"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.05520-11"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00616-09"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1086\/513203"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00042-09"},{"issue":"2","key":"e_1_3_5_27_1","first-page":"269","article-title":"Vancomycin resistance in Staphylococcus aureus","volume":"90","author":"McGuinness WA","year":"2017","unstructured":"McGuinness WA, Malachowa N, DeLeo FR. Vancomycin resistance in Staphylococcus aureus. Yale J Biol Med. 2017 Jun;90(2):269\u2013281.","journal-title":"Yale J Biol Med"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/ja.2014.111"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-69058-z"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir935"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00113-08"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.42.6.2398-2402.2004"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02512-17"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmii.2011.11.006"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0136082"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a026997"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15257-1"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1086\/600039"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit582"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa053783"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00307-09"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00030-13"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1086\/430352"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.37201\/req\/s01.09.2021"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00551-07"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.2217\/fmb-2019-0332"},{"key":"e_1_3_5_47_1","first-page":"3","article-title":"Mechanisms of action and antimicrobial activity of ceftobiprole","volume":"32","author":"Morosini MI","year":"2019","unstructured":"Morosini MI, Diez-Aguilar M, Canton R. Mechanisms of action and antimicrobial activity of ceftobiprole. Rev Esp Quimioter. 2019 Sep;32 Suppl 3:3\u201310.","journal-title":"Rev Esp Quimioter"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S56616"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02371-13"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2017.01.019"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1177\/1060028016664361"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1086\/427283"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.1086\/526772"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2017.07.028"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2020.08.025"},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-14-14"},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy774"},{"key":"e_1_3_5_58_1","unstructured":"A Phase 3 Telavancin Staphylococcus Aureus (S. Aureus) Bacteremia Trial. 2020. Accessed 15 10 2021. [cited; Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT02208063"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S164515"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.1086\/595686"},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(07)70094-4"},{"key":"e_1_3_5_62_1","article-title":"Trimethoprim Sulfamethoxazole","author":"Kemnic TR","year":"2021","unstructured":"Kemnic TR, Coleman M, Trimethoprim Sulfamethoxazole, StatPearls, 2021;Treasure Island (FL)","journal-title":"StatPearls"},{"key":"e_1_3_5_63_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-117-5-390"},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h2219"},{"key":"e_1_3_5_65_1","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/5.Supplement_3.S407"},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00034-09"},{"key":"e_1_3_5_67_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01746-18"},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.1093\/femspd\/ftw019"},{"key":"e_1_3_5_69_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.5.1059"},{"key":"e_1_3_5_70_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/151.1.157"},{"key":"e_1_3_5_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32456-X"},{"key":"e_1_3_5_72_1","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a025247"},{"key":"e_1_3_5_73_1","article-title":"Beta Lactam Antibiotics","author":"Pandey N","year":"2021","unstructured":"Pandey N, Cascella M, Beta Lactam Antibiotics, StatPearls, 2021;Treasure Island (FL)","journal-title":"StatPearls"},{"key":"e_1_3_5_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2014.08.003"},{"key":"e_1_3_5_75_1","doi-asserted-by":"publisher","DOI":"10.1128\/jb.165.2.373-378.1986"},{"key":"e_1_3_5_76_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-014-0023-0"},{"key":"e_1_3_5_77_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.0103"},{"key":"e_1_3_5_78_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01816-17"},{"key":"e_1_3_5_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2021.106310"},{"key":"e_1_3_5_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2014.05.061"},{"key":"e_1_3_5_81_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02483-18"},{"key":"e_1_3_5_82_1","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a025262"},{"key":"e_1_3_5_83_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu580"},{"key":"e_1_3_5_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2018.01.010"},{"key":"e_1_3_5_85_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02633-17"},{"key":"e_1_3_5_86_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1081"},{"key":"e_1_3_5_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/0732-8893(84)90002-6"},{"key":"e_1_3_5_88_1","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.02585-14"},{"key":"e_1_3_5_89_1","doi-asserted-by":"publisher","DOI":"10.1086\/675283"},{"key":"e_1_3_5_90_1","doi-asserted-by":"publisher","DOI":"10.1128\/iai.65.10.4146-4151.1997"},{"key":"e_1_3_5_91_1","doi-asserted-by":"publisher","DOI":"10.1128\/iai.64.5.1659-1665.1996"},{"key":"e_1_3_5_92_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jp.7211496"},{"key":"e_1_3_5_93_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00570-07"},{"key":"e_1_3_5_94_1","unstructured":"Nabi Biopharmaceuticals Announces Results of StaphVAX\u00ae Confirmatory Phase III Clinical Trial. 2005. Accessed 5 11 2021. [cited; Available from: https:\/\/www.sec.gov\/Archives\/edgar\/data\/72444\/000119312505214434\/dex99.htm"},{"key":"e_1_3_5_95_1","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.70.9.4987-4996.2002"},{"key":"e_1_3_5_96_1","doi-asserted-by":"publisher","DOI":"10.1128\/CDLI.7.1.14-20.2000"},{"key":"e_1_3_5_97_1","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.69.5.3120-3127.2001"},{"key":"e_1_3_5_98_1","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.70.6.2758-2762.2002"},{"key":"e_1_3_5_99_1","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.71.12.6864-6870.2003"},{"key":"e_1_3_5_100_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2004.08.015"},{"key":"e_1_3_5_101_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00096-06"},{"issue":"5","key":"e_1_3_5_102_1","first-page":"455","article-title":"Drug evaluation: tefibazumab\u2013a monoclonal antibody against staphylococcal infection","volume":"8","author":"John JF","year":"2006","unstructured":"John JF. Drug evaluation: tefibazumab\u2013a monoclonal antibody against staphylococcal infection. Curr Opin Mol Ther. 2006 ;8(5):455\u2013460.","journal-title":"Curr Opin Mol Ther"},{"key":"e_1_3_5_103_1","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00575-13"},{"key":"e_1_3_5_104_1","doi-asserted-by":"publisher","DOI":"10.1128\/JB.00735-17"},{"key":"e_1_3_5_105_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0190537"},{"key":"e_1_3_5_106_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofw172.1057"},{"key":"e_1_3_5_107_1","unstructured":"XBiotech announces top-line results for 514G3 antibody therapy in serious Staphylococcus aureus infections. 2017. Accessed 19 10 2021. [cited; Available from: https:\/\/www.globenewswire.com\/news-release\/2017\/04\/03\/953500\/0\/en\/XBiotech-Announces-Top-Line-Results-for-514G3-Antibody-Therapy-in-Serious-Staphylococcus-aureus-Infections.html"},{"key":"e_1_3_5_108_1","doi-asserted-by":"publisher","DOI":"10.1002\/emmm.201100123"},{"key":"e_1_3_5_109_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02245-17"},{"key":"e_1_3_5_110_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature16057"},{"key":"e_1_3_5_111_1","doi-asserted-by":"publisher","DOI":"10.1038\/nchem.2635"},{"key":"e_1_3_5_112_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2016.1229722"},{"key":"e_1_3_5_113_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02588-18"},{"key":"e_1_3_5_114_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa439.1488"},{"key":"e_1_3_5_115_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01097-10"},{"key":"e_1_3_5_116_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2012.10.011"},{"key":"e_1_3_5_117_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00731-18"},{"key":"e_1_3_5_118_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02232-13"},{"key":"e_1_3_5_119_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02629-16"},{"key":"e_1_3_5_120_1","unstructured":"A study to evaluate the safety PK PD immunogenicity of N-Rephasin\u00ae SAL200 in healthy male Volunteers. 2021. Accessed 5 11 2021. [cited; Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT03446053"},{"key":"e_1_3_5_121_1","unstructured":"Phase iia clinical study of N-Rephasin\u00ae SAL200. 2021. Accessed 5 11 2021. [cited; Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT03089697"},{"key":"e_1_3_5_122_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit637"},{"key":"e_1_3_5_123_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02666-16"},{"key":"e_1_3_5_124_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02291-18"},{"key":"e_1_3_5_125_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01885-19"},{"key":"e_1_3_5_126_1","unstructured":"Exebacase Pipeline. 2021. Accessed 11 11 2021. [cited; Available from: https:\/\/www.contrafect.com\/pipeline\/exebacase"},{"key":"e_1_3_5_127_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI136577"},{"key":"e_1_3_5_128_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-017-0156-z"},{"key":"e_1_3_5_129_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir1047"},{"key":"e_1_3_5_130_1","unstructured":"Oritavancin for Staphylococcus Aureus Infections in Opioid Users. 2018. Accessed 21 1 2022. [cited; Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03761953"},{"key":"e_1_3_5_131_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2018.1519021"},{"key":"e_1_3_5_132_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01634-16"},{"key":"e_1_3_5_133_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01144-10"},{"issue":"12","key":"e_1_3_5_134_1","first-page":"3398","article-title":"Efficacy of chimeric ectolysin P128 in drug-resistant Staphylococcus aureus bacteraemia in mice","volume":"73","author":"Channabasappa S","year":"2018","unstructured":"Channabasappa S, Chikkamadaiah R, Durgaiah M, et al. Efficacy of chimeric ectolysin P128 in drug-resistant Staphylococcus aureus bacteraemia in mice. J Antimicrob Chemother. 2018 Dec 1;73(12):3398\u20133404.","journal-title":"J Antimicrob Chemother"},{"key":"e_1_3_5_135_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep40182"},{"key":"e_1_3_5_136_1","unstructured":"ContraFect announces U.S. FDA grants breakthrough therapy designation to exebacase for the treatment of methicillin-resistant staphylococcus aureus (mrsa) bacteremia including right-sided endocarditis. 2020. Accessed 11 11 2021. [cited; Available from: https:\/\/www.globenewswire.com\/en\/news-release\/2020\/02\/24\/1989110\/0\/en\/ContraFect-Announces-U-S-FDA-Grants-Breakthrough-Therapy-Designation-to-Exebacase-for-the-Treatment-of-Methicillin-Resistant-Staphylococcus-aureus-MRSA-Bacteremia-Including-Right-S.html"},{"key":"e_1_3_5_137_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab452"}],"container-title":["Expert Opinion on Investigational Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543784.2022.2040015","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T06:24:42Z","timestamp":1772778282000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543784.2022.2040015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,14]]},"references-count":135,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3,4]]}},"alternative-id":["10.1080\/13543784.2022.2040015"],"URL":"https:\/\/doi.org\/10.1080\/13543784.2022.2040015","relation":{},"ISSN":["1354-3784","1744-7658"],"issn-type":[{"value":"1354-3784","type":"print"},{"value":"1744-7658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,14]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-11-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}